Just as Novartis AG’s best-selling medicines are losing patent protection, the company is poised to get a revenue boost from a U.S. program designed to speed life- saving therapies to patients with few treatment options.
Senate hearings, lawsuits and an Internal Revenue Service questionnaire are placing new scrutiny on nonprofit groups that spend millions of dollars on political campaigns without disclosing their donors.
In trying to get sophisticated medicines to its neediest citizens, India is increasingly pitting its generic-pharmaceutical industry against international drugmakers, threatening their growth in emerging markets.
The cost of caring for dementia patients has reached $109 billion annually, exceeding that for heart disease and cancer, and will double by the time the youngest Baby Boomers reach their 70s, according to a study.
President Barack Obama announced a U.S. campaign that may lead to new treatments for some of the least understood brain disorders, benefiting efforts by Pfizer Inc., Roche Holding AG and Eli Lilly & Co.
Ex-InterMune Inc. Chief Executive Officer W. Scott Harkonen’s fraud conviction for disseminating misleading information about a drug’s clinical trial was upheld by an appeals court that rejected his free speech arguments.
Drug companies and medical-device makers would be forced to publicly disclose any money paid to doctors under new U.S. regulations designed to make patients aware of conflicts of interest that may affect their health.
President Barack Obama raised $738.5 million for his successful re-election effort, almost as much as the record $745 million he brought in four years earlier, Federal Election Commission filings show.
Pharmaceutical Research And Manufacturers Of America Photos